| DC67045 |
Solriamfetol
Featured
|
Solriamfetol (JZP-110) is a selective dopamine and norepinephrine reuptake inhibitor with robust wake-promoting effects. Solriamfetol binds to dopamine and norepinephrine transporters, so it can inhibit reuptake of dopamine and norepinephrine. Solriamfetol treatment significantly improves the ability to stay awake and subjective symptoms of excessive sleepiness in adults with narcolepsy. |
|
| A415 |
Spartalizumab Biosimilar(Anti-PDCD1 / PD-1 / CD279 Reference Antibody)
Featured
|
Spartalizumab (PDR001) is a humanized immunoglobulin 4 monoclonal antibody that binds PD-1 with subnanomolar activity and blocks interaction with PD-L1 and PD-L2. Spartalizumab can be used for the research of anaplastic thyroid carcinoma (ATC). |
|
| A416 |
Pimivalimab Biosimilar(Anti-PDCD1 / PD-1 / CD279 Reference Antibody)
Featured
|
Pimivalimab (JTX-4014) is a PD-1 inhibitor. Pimivalimab can be used for the research of solid tumor. |
|
| A417 |
Toripalimab Biosimilar(Anti-PDCD1 / PD-1 / CD279 Reference Antibody)
Featured
|
Toripalimab is the first domestic anti-tumor PD-1 antibody in China. Toripalimab is a selective, recombinant, humanized monoclonal antibody against PD-1. Toripalimab is able to bind to PD-1 and block the interaction with its ligands. Toripalimab has exhibited primary anti-tumor effects in tumors such as melanoma, lung cancer, digestive tract tumors, hepatobiliary and pancreatic tumors, neuroendocrine neoplasms, nasopharyngeal carcinoma and urothelial carcinoma. |
|
| A418 |
Zimberelimab Biosimilar(Anti-PDCD1 / PD-1 / CD279 Reference Antibody)
Featured
|
Zimberelimab (GLS-010) is a fully human IgG4 anti-PD-1 monoclonal antibody with an EC50 of 210 pM for human PD-1. Zimberelimab effectively blocks the binding of PD-L1 and PD-L2 to cell-surface PD-1 in CHO-S cells, with IC50 values of 580 pM and 670 pM, respectively. Zimberelimab shows antitumor activities, and can be used for various cancers research, including cervical cancer, non-small cell lung cancer and classical Hodgkin’s lymphoma. |
|
| A419 |
Prolgolimab Biosimilar(Anti-PDCD1 / PD-1 / CD279 Reference Antibody)
Featured
|
Prolgolimab (BCD-100) is a human IgG1 anti-PD-1 monoclonal antibody containing the Fc-silencing 'LALA' mutation. Prolgolimab can be used for the research of advanced melanoma. |
|
| A420 |
Nofazinlimab Biosimilar(Anti-PDCD1 / PD-1 / CD279 Reference Antibody)
Featured
|
Nofazinlimab (CS1003) is a humanised IgG4 anti-PD-1 monoclonal antibody. Nofazinlimab can be used for unresectable hepatocellular carcinoma (uHCC) research. |
|
| A421 |
Cetrelimab
Featured
|
Cetrelimab (JNJ 63723283; JNJ 3283) is a human IgG4κ mAb targeting PD-1. Cetrelimab binds PD-1 (Kd=1.72 nM, HEK293) to block the interaction of PD-1 with PD-L1 and PD-L2 (IC50s=111.7 ng/mL and 138.6 ng/mL, respectively). Cetrelimab stimulates peripheral T cells, increases IFN-γ, IL-2, TNF-α level and inhibits tumor growth in vivo. |
|
| A422 |
Budigalimab
Featured
|
Budigalimab (ABBV 181; PR 1648817) is a humanized IgG1 monoclonal antibody targeting programmed cell death 1 (PD-1) receptor. Budigalimab is Fc mutated thus to reduce Fc receptor interactions and limit effector function. |
|
| A423 |
Ezabenlimab
Featured
|
Ezabenlimab (BI-754091) is an anti-PD-1 mAb with binding constant Kd value of 6 nM (CHO cells). Ezabenlimab blocks the interaction of PD-1 with PD-L1 and PD-L2. Ezabenlimab increases interferon-γ secretion in T cells, and inhibits tumor growth in vivo. |
|
| A424 |
Serplulimab
Featured
|
Serplulimab (HLX 10) is humanized monoclonal anti-PD-1 antibody. Serplulimab can be used in research of small cell lung cancer. |
|
| A425 |
Penpulimab
Featured
|
Penpulimab is an IgG1 backbone anti-PD-1 monoclonal antibody with antitumor activities. |
|
| A426 |
Balstilimab
Featured
|
Balstilimab (AGEN2034) is a fully human monoclonal IgG4 antibody against PD-1. |
|
| A427 |
UCB patent anti-PD-1
Featured
|
|
|
| A428 |
Anti-PDGFB Antibody (MOR-8457)
Featured
|
|
|
| A429 |
Thrombogenics patent anti-PDGF-C
Featured
|
|
|
| A430 |
Olaratumab
Featured
|
Olaratumab (IMC-3G3; LY3012207) is an anti-platelet-derived growth factor receptor alpha (PDGFRα) human monoclonal IgG1 antibody with antitumor activity. |
|
| A431 |
Tovetumab
Featured
|
Tovetumab (MEDI-575) is an anti-PDGFRα monoclonal antibody that selectively blocks the PDGFRα signal transduction. Tovetumab can be used in the research of glioblastoma and non-small cell lung cancer (NSCLC). |
|
| A432 |
Anti-PDGFRB/CD140b Antibody (IMC-2C5)
Featured
|
|
|
| A433 |
Novo Nordisk patent anti-PGLYRP1
Featured
|
|
|
| A434 |
Bavituximab
Featured
|
Bavituximab (Anti-Human Phosphatidylserine Recombinant Antibody) is a phosphatidylserine (PS)-targeting monoclonal antibody, suppresses tumor growth by targeting tumor vasculature and reactivating antitumor immunity. Bavituximab plus Paclitaxel (HY-B0015) and Carboplatin (HY-17393), have enhanced inhibition on non-small-cell lung cancer. |
|
| A435 |
ATH3G10
Featured
|
|
|
| A436 |
Diaccurate patent anti-sPLA2-GIB
Featured
|
|
|
| A437 |
ATN-658
Featured
|
|
|
| A438 |
Genentech anti-PMEL17
Featured
|
|
|
| A439 |
Novartis patent anti-PMEL17
Featured
|
|
|
| A440 |
Genentech patent anti-Polyubiquitin
Featured
|
|
|
| A441 |
Eureka patent anti-PRAME
Featured
|
|
|
| A442 |
BAY-1158061
Featured
|
|
|
| A443 |
Rolinsatamab
Featured
|
Rolinsatamab is a IgG1κ type chimeric antibody targeting to PRLR (prolactin receptor). Rolinsatamab can be conjugated with pyrrolobenzodiazepine (PDB) dimer SGD-1882 (HY-101127) via a cleavable maleimidocaproyl type linker, to form an antibody-drug conjugate, Rolinsatamab talirine. One Rolinsatamab talirine has an average of 2 site-specific drug attachment engineered cysteines (C242, C242'). The linker equips the valine-alanine dipeptide, as cathepsine B cleavage site. on an average of 2 site-specific drug attachment engineered cysteines (C242, C242'). |
|
